204 related articles for article (PubMed ID: 35849035)
1. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Lassman AB; Pugh SL; Wang TJC; Aldape K; Gan HK; Preusser M; Vogelbaum MA; Sulman EP; Won M; Zhang P; Moazami G; Macsai MS; Gilbert MR; Bain EE; Blot V; Ansell PJ; Samanta S; Kundu MG; Armstrong TS; Wefel JS; Seidel C; de Vos FY; Hsu S; Cardona AF; Lombardi G; Bentsion D; Peterson RA; Gedye C; Bourg V; Wick A; Curran WJ; Mehta MP
Neuro Oncol; 2023 Feb; 25(2):339-350. PubMed ID: 35849035
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB; van den Bent MJ; Gan HK; Reardon DA; Kumthekar P; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Ansell PJ; Bain E; Holen KD; Maag D; Merrell R
Neuro Oncol; 2019 Jan; 21(1):106-114. PubMed ID: 29982805
[TBL] [Abstract][Full Text] [Related]
3. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.
Van Den Bent M; Eoli M; Sepulveda JM; Smits M; Walenkamp A; Frenel JS; Franceschi E; Clement PM; Chinot O; De Vos F; Whenham N; Sanghera P; Weller M; Dubbink HJ; French P; Looman J; Dey J; Krause S; Ansell P; Nuyens S; Spruyt M; Brilhante J; Coens C; Gorlia T; Golfinopoulos V
Neuro Oncol; 2020 May; 22(5):684-693. PubMed ID: 31747009
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial.
Narita Y; Muragaki Y; Kagawa N; Asai K; Nagane M; Matsuda M; Ueki K; Kuroda J; Date I; Kobayashi H; Kumabe T; Beppu T; Kanamori M; Kasai S; Nishimura Y; Xiong H; Ocampo C; Yamada M; Mishima K
Cancer Sci; 2021 Dec; 112(12):5020-5033. PubMed ID: 34609773
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M; Gan HK; Lassman AB; Kumthekar P; Merrell R; Butowski N; Lwin Z; Mikkelsen T; Nabors LB; Papadopoulos KP; Penas-Prado M; Simes J; Wheeler H; Walbert T; Scott AM; Gomez E; Lee HJ; Roberts-Rapp L; Xiong H; Bain E; Ansell PJ; Holen KD; Maag D; Reardon DA
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1209-1217. PubMed ID: 29075855
[TBL] [Abstract][Full Text] [Related]
6. Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma.
Clement PMJ; Dirven L; Eoli M; Sepulveda-Sanchez JM; Walenkamp AME; Frenel JS; Franceschi E; Weller M; Chinot O; De Vos FYFL; Whenham N; Sanghera P; Looman J; Kundu MG; Peter de Geus J; Nuyens S; Spruyt M; Gorlia T; Coens C; Golfinopoulos V; Reijneveld JC; van den Bent MJ
Eur J Cancer; 2021 Apr; 147():1-12. PubMed ID: 33601293
[TBL] [Abstract][Full Text] [Related]
7. A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Vize CJ; Kim SK; Matthews T; Macsai M; Merrell R; Hsu S; Kundu MG; Yoon J; Kennedy E; Pai M; Bain E; Lassman AB; Moazami G
Ophthalmic Res; 2023; 66(1):1030-1043. PubMed ID: 37257422
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
[TBL] [Abstract][Full Text] [Related]
9. Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate.
Phillips AC; Boghaert ER; Vaidya KS; Falls HD; Mitten MJ; DeVries PJ; Benatuil L; Hsieh CM; Meulbroek JA; Panchal SC; Buchanan FG; Durbin KR; Voorbach MJ; Reuter DR; Mudd SR; Loberg LI; Ralston SL; Cao D; Gan HK; Scott AM; Reilly EB
Mol Cancer Ther; 2018 Apr; 17(4):795-805. PubMed ID: 29483208
[TBL] [Abstract][Full Text] [Related]
10. Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR.
Vaidya KS; Mitten MJ; Zelaya-Lazo AL; Oleksijew A; Alvey C; Falls HD; Mishra S; Palma J; Ansell P; Phillips AC; Reilly EB; Anderson M; Boghaert ER
J Neurooncol; 2021 Apr; 152(2):233-243. PubMed ID: 33517558
[TBL] [Abstract][Full Text] [Related]
11. An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
Mittapalli RK; Stodtmann S; Friedel A; Menon RM; Bain E; Mensing S; Xiong H
J Clin Pharmacol; 2019 Sep; 59(9):1225-1235. PubMed ID: 30990907
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma.
Marin BM; Porath KA; Jain S; Kim M; Conage-Pough JE; Oh JH; Miller CL; Talele S; Kitange GJ; Tian S; Burgenske DM; Mladek AC; Gupta SK; Decker PA; McMinn MH; Stopka SA; Regan MS; He L; Carlson BL; Bakken K; Burns TC; Parney IF; Giannini C; Agar NYR; Eckel-Passow JE; Cochran JR; Elmquist WF; Vaubel RA; White FM; Sarkaria JN
Neuro Oncol; 2021 Dec; 23(12):2042-2053. PubMed ID: 34050676
[TBL] [Abstract][Full Text] [Related]
13. Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma.
Gan HK; Reardon DA; Lassman AB; Merrell R; van den Bent M; Butowski N; Lwin Z; Wheeler H; Fichtel L; Scott AM; Gomez EJ; Fischer J; Mandich H; Xiong H; Lee HJ; Munasinghe WP; Roberts-Rapp LA; Ansell PJ; Holen KD; Kumthekar P
Neuro Oncol; 2018 May; 20(6):838-847. PubMed ID: 29077941
[TBL] [Abstract][Full Text] [Related]
14. Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO).
Padovan M; Eoli M; Pellerino A; Rizzato S; Caserta C; Simonelli M; Michiara M; Caccese M; Anghileri E; Cerretti G; Rudà R; Zagonel V; Lombardi G
Cancers (Basel); 2021 Jun; 13(11):. PubMed ID: 34204877
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
She L; Gong X; Su L; Liu C
Oncologist; 2023 Jan; 28(1):e45-e53. PubMed ID: 36181764
[TBL] [Abstract][Full Text] [Related]
16. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
[TBL] [Abstract][Full Text] [Related]
17. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
[TBL] [Abstract][Full Text] [Related]
18. Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.
Porath KA; Regan MS; Griffith JI; Jain S; Stopka SA; Burgenske DM; Bakken KK; Carlson BL; Decker PA; Vaubel RA; Dragojevic S; Mladek AC; Connors MA; Hu Z; He L; Kitange GJ; Gupta SK; Feldsien TM; Lefebvre DR; Agar NYR; Eckel-Passow JE; Reilly EB; Elmquist WF; Sarkaria JN
Neurooncol Adv; 2022; 4(1):vdac130. PubMed ID: 36071925
[TBL] [Abstract][Full Text] [Related]
19. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
Wang Y; Pan L; Sheng XF; Chen S; Dai JZ
Asia Pac J Clin Oncol; 2016 Mar; 12(1):e23-9. PubMed ID: 24571331
[TBL] [Abstract][Full Text] [Related]
20. Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFR
von Achenbach C; Silginer M; Blot V; Weiss WA; Weller M
Mol Cancer Ther; 2020 Jun; 19(6):1328-1339. PubMed ID: 32371586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
